INVestIgation of rheumatiC AF Treatment Using vitamin K antagonists, rivaroxaban or aspirin Studies
To determine if:
1. In patients with rheumatic valvular heart disease (RVHD) and who are in atrial fibrillation or flutter (AF/flutter) and have other stroke risk factors, rivaroxaban is non-inferior to vitamin K antagonists (VKAs) for prevention of stroke or systemic embolism.
2. In patients with RVHD, either with AF/flutter but unsuitable for VKA therapy, or with sinus rhythm but with high risk, rivaroxaban is superior to aspirin for prevention of stroke or systemic embolism.
One registry and two randomized, parallel group, open-label clinical trials
Registry: 17,000 patients
Trials: 4,500 patients
Stroke and systemic embolism
Stuart J Connolly
Sumathy Rangarajan, Gayle Lewis
Amy Krol, Divya Hari